Redhill Biopharma (RDHL) Expected to Announce Earnings on Thursday

Redhill Biopharma (NASDAQ:RDHL) is expected to announce its H2 24/25 results before the market opens on Thursday, April 9th. Analysts expect the company to announce earnings of ($474.2857) per share and revenue of $24.5140 million for the quarter. Interested persons may visit the the company’s upcoming H2 24/25 earning results page for the latest details on the call scheduled for Wednesday, April 8, 2026 at 6:00 PM ET.

Redhill Biopharma Stock Performance

NASDAQ:RDHL opened at $0.81 on Thursday. The firm’s fifty day moving average is $0.99 and its two-hundred day moving average is $1.24. The firm has a market cap of $4.15 million, a price-to-earnings ratio of 0.00 and a beta of 4.92. Redhill Biopharma has a one year low of $0.71 and a one year high of $3.31.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Redhill Biopharma in a report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

About Redhill Biopharma

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.